Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
Citi cuts GSK target price after Arexy disappointment, but stays at 'buy'
(Sharecast News) - Citi has reiterated its 'buy' rating on GSK despite a flurry of disappointing news for the biopharma giant in recent weeks, though the bank has slashed its target price for the stock by more than 10%. Shares took a tumble last week after a ruling by a US health agency narrowed usage recommendations for all respiratory syncytial virus (RSV) vaccines, restricting the addressable market for GSK's Arexvy product.
The US Advisory Committee on Immunisation Practices (ACIP) said it was tightening its recommendations for adults in the 60-74 age category to those at risk of severe RSV, following feedback from the medical community. The ruling replaces the prior blanket "60+" years recommendation. Meanwhile, a decision to extend the usage of RSV vaccines to those aged 50-59 was postponed pending more safety data.
Citi said the decision "delivered a blow" to Arexy, as it removed its own revaccination assumptions (previously assumed at 5-10%) and its reduced peak sales estimate to £2.2bn (previously £2.9bn).
Meanwhile, ongoing litigation concerns related to formed heartburn drug Zantac continue to weigh on the stock, as the company continues to work through tens of thousands of personal injury claims.
"We had previously argued GSK had set itself up to beat and raise through 2024, based on the vaccine/oncology launches and HIV/respiratory dynamics, which now seems less likely," said analyst Peter Verdult.
"Although the £7bn market cap loss on rising Zantac litigation concerns feels harsh (our price target assumes a £2.4bn settlement), the resulting sentiment overhang will weigh on the shares."
The bank remains optimistic over the long term but has cut its price target to 1,900p from 2,120p.
GSK's shares were up 0.8% at 1,522.5p by 0927 BST.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity, Equity & Inclusion | Doing Business with Fidelity | Diversity, Equity & Inclusion Reports | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Staying secure | Statutory and Regulatory disclosures | Whistleblowing programme
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.